Our leadership team has a proven track record in all aspects of drug development, regulatory approval, and commercialization, with focus on placing patients first, and high-speed execution in commercialization.
We are committed to leadership in resolving serious, unmet medical needs for the betterment of overall human health. Our mission is to make a significant difference for patients with high unmet medical needs, focusing on oncology. Our lead pipeline product candidate is a novel, bispecific antibody targeting both PD-1 and VEGF, ivonescimab. Summit has enacted the path to helping patients while creating opportunities for durable growth as a company by initiating two Phase III trials with the novel drug, ivonescimab.
In January 2023, we finalized our collaboration and license agreement with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”) for ivonescimab. The Summit license territories for ivonescimab include the United States, Canada, the EU, and Japan. We initiated two Phase III clinical trials with ivonescimab in 2023 and are positioning the company to advance its oncology pipeline in 2024 and beyond.